For the Inventor, By the Inventor

Enter assignee name

Copenhagen, Denmark

Genmab A+s

USPTO Granted Patents = 107

CIPO Patents = 62

EPO Patents = 66

Trademarks = 33

Forward Citations = 1,024

Loading Chart...

Loading Chart...

271 inventors (with patents filed for the assignee):

Paul Parren (78 out of 127 patents)

Janine Schuurman (42 out of 53 patents)

Jan Van De Winkel (32 out of 45 patents)

4. David Satijn (29 out of 41 patents)

5. Aran Frank Labrijn (29 out of 36 patents)

6. Ole Baadsgaard (28 out of 31 patents)

7. Edward Norbert Van Den Brink (25 out of 54 patents)

8. Rik Rademaker (15 out of 27 patents)

9. Isil Altintas (15 out of 16 patents)

10. Joyce Meesters (15 out of 15 patents)

11. Tom Vink (15 out of 26 patents)

12. Jan G J Van De Winkel (15 out of 15 patents)

13. Joost J Neijssen (15 out of 15 patents)

14. Ugur Sahin (13 out of 182 patents)

15. Patrick Van Berkel (13 out of 14 patents)

Core Competencies:

Bispecific Antibodies

Monoclonal Antibodies

Heterodimeric Antibodies

Cancer Treatment

Antibody-Drug Conjugates

CD3 Binding Agents

PD-1 Antibodies

CD137 Modulation

Tumor Necrosis Factor

Fibroblast Activation Protein

EpCAM Binding Agents

Humanized Antibodies

107 patents: Sort by Forward Citations

1. 12453781 - Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate (2025-10-28),

2. 12435154 - Bispecific antibodies against CD3 and CD20 (2025-10-07),

3. 12421319 - Binding agents that bind OX40 (CD134) and method of use thereof to treat disease (2025-09-23),

4. 12415859 - Methods of producing heterodimeric antibodies (2025-09-16),

5. 12398214 - Binding agents binding to EpCAM and CD137 (2025-08-26),

6. 12351650 - Antibodies binding to fibroblast activation protein alpha and death receptor 4 (2025-07-08),

7. 12324841 - Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate (2025-06-10),

8. 12247065 - Method for producing a controlled mixture of two or more different antibodies (2025-03-11),

9. 12246025 - Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate (2025-03-11),

10. 12115227 - Formulation for antibody and drug conjugate thereof (2024-10-15),

11. 12077596 - Multispecific antibodies against CD40 and CD137 (2024-09-03),

12. 11970544 - Antibodies (2024-04-30),

13. 11939388 - Multispecific antibodies against CD40 and CD137 (2024-03-26),

14. 11932693 - Monoclonal antibodies directed against programmed death-1 protein and their use in medicine (2024-03-19),

15. 11866514 - Heterodimeric antibody Fc-containing proteins and methods for production thereof (2024-01-09),

Genmab is an international biotechnology company that specializes in the research, development, and commercialization of antibody-based therapies to treat cancer. The company focuses on creating innovative and differentiated antibody products to address unmet medical needs. With a diverse pipeline and a track record of successful collaborations, Genmab is committed to improving the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

107 Patents

#4 in Copenhagen

#35 in Denmark

#7,106 in the World

Copenhagen, Denmark

Genmab A+s

Forward Citations = 1,024

271 inventors:

Paul Parren (78 out of 127 patents)

Janine Schuurman (42 out of 53 patents)

Jan Van De Winkel (32 out of 45 patents)

4. David Satijn (29 out of 41 patents)

5. Aran Frank Labrijn (29 out of 36 patents)

Please report any incorrect information to support@idiyas.com

Loading…